Amsterdam, the Netherlands, 17 June 2015. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of Neuravi Ltd., a private Irish company commercializing innovative neurointerventional therapies for stroke. The syndicate, led by LSP with participation from existing investors Fountain Healthcare Partners, Delta Partners and the Western Development Commission will invest EUR 19 million.
Neuravi’s stroke therapy platform, the EmboTrap® Revascularization Device, has been developed to help Stroke Doctors treat patients very quickly after ischemic stroke onset by removing the lodged blood clot from the brain. The EmboTrap® Revascularization Device is CE approved and has been used in over 150 patients to date with great success. This funding will support European commercialization of the device, as well as supporting Neuravi’s pivotal clinical trial, ARISE II, which will begin enrolling patients this year at select centers in the United States and Europe.
A PDF version of Neuravi’s press release can be found here.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over USD 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.